CVS CEO Faces Aetna Challenge Amid Health News Highlights

David Joyner, the newly appointed CEO of CVS Health, faces scrutiny over his ability to turn around the struggling Aetna division amidst rising medical costs. Meanwhile, WHO declares Egypt malaria-free, Sanofi discusses Opella's sale, and Novo Nordisk releases promising diabetes study results.

David Joyner takes the helm as CEO of CVS Health, instigating analyst skepticism regarding his capability to address Aetna's challenges due to heightened medical expenses. His prior role as head of Caremark pharmacy benefit management is under intense examination as he assumes his new duties.

Significant developments in global health include the World Health Organization's announcement certifying Egypt as free from malaria. Previously, the disease was a long-standing health challenge, but successful eradication efforts have led to this certification, marking a historic achievement for the nation.

Further, French pharmaceutical giant Sanofi is in exclusive negotiations with CD&R to divest a controlling stake in its consumer health unit Opella for $17 billion. This sale could reshape the competitive landscape of the pharmaceutical industry should the deal reach finalization.

(With inputs from agencies.)